Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene.

Drobes DJ, Anton RF, Thomas SE, Voronin K.

Neuropsychopharmacology. 2003 Apr;28(4):755-64.

2.

Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers.

Drobes DJ, Anton RF, Thomas SE, Voronin K.

Alcohol Clin Exp Res. 2004 Sep;28(9):1362-70.

PMID:
15365307
3.

Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking.

Anton RF, Drobes DJ, Voronin K, Durazo-Avizu R, Moak D.

Psychopharmacology (Berl). 2004 Apr;173(1-2):32-40.

PMID:
14722705
4.

Nalmefene. Alcohol dependence: no advance.

[No authors listed]

Prescrire Int. 2014 Jun;23(150):150-2.

PMID:
25121147
5.

Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.

Anton RF, Voronin KK, Randall PK, Myrick H, Tiffany A.

Alcohol Clin Exp Res. 2012 Nov;36(11):2000-7. doi: 10.1111/j.1530-0277.2012.01807.x.

6.

A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.

Gual A, He Y, Torup L, van den Brink W, Mann K; ESENSE 2 Study Group..

Eur Neuropsychopharmacol. 2013 Nov;23(11):1432-42. doi: 10.1016/j.euroneuro.2013.02.006.

PMID:
23562264
7.

Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control.

Voronin K, Randall P, Myrick H, Anton R.

Alcohol Clin Exp Res. 2008 Nov;32(11):1954-61. doi: 10.1111/j.1530-0277.2008.00783.x.

8.

Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis.

Soyka M, Friede M, Schnitker J.

Pharmacopsychiatry. 2016 Mar;49(2):66-75. doi: 10.1055/s-0035-1565184.

PMID:
26845589
9.

Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.

Mann K, Bladström A, Torup L, Gual A, van den Brink W.

Biol Psychiatry. 2013 Apr 15;73(8):706-13. doi: 10.1016/j.biopsych.2012.10.020.

PMID:
23237314
10.

A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence.

Anton RF, Pettinati H, Zweben A, Kranzler HR, Johnson B, Bohn MJ, McCaul ME, Anthenelli R, Salloum I, Galloway G, Garbutt J, Swift R, Gastfriend D, Kallio A, Karhuvaara S.

J Clin Psychopharmacol. 2004 Aug;24(4):421-8.

PMID:
15232334
11.

A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.

Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E.

Alcohol Clin Exp Res. 1994 Oct;18(5):1162-7.

PMID:
7847600
12.

Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.

Karhuvaara S, Simojoki K, Virta A, Rosberg M, Löyttyniemi E, Nurminen T, Kallio A, Mäkelä R.

Alcohol Clin Exp Res. 2007 Jul;31(7):1179-87.

PMID:
17451401
13.

[Benefits in reducing alcohol consumption: how nalmefene can help].

Bendimerad P, Blecha L.

Encephale. 2014 Dec;40(6):495-500. doi: 10.1016/j.encep.2014.10.012. Review. French. Erratum in: Encephale. 2015 Jun;41(3):284.

PMID:
25454365
14.

Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.

Tidey JW, Monti PM, Rohsenow DJ, Gwaltney CJ, Miranda R Jr, McGeary JE, MacKillop J, Swift RM, Abrams DB, Shiffman S, Paty JA.

Alcohol Clin Exp Res. 2008 Jan;32(1):58-66.

15.

Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study.

van den Brink W, Sørensen P, Torup L, Mann K, Gual A; SENSE Study Group..

J Psychopharmacol. 2014 Aug;28(8):733-44. doi: 10.1177/0269881114527362.

PMID:
24671340
16.

Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies.

van den Brink W, Aubin HJ, Bladström A, Torup L, Gual A, Mann K.

Alcohol Alcohol. 2013 Sep-Oct;48(5):570-8. doi: 10.1093/alcalc/agt061. Erratum in: Alcohol Alcohol. 2013 Nov-Dec;48(6):746.

17.

Can alcohol dependent patients adhere to an 'as-needed' medication regimen?

Sinclair J, Chick J, Sørensen P, Kiefer F, Batel P, Gual A.

Eur Addict Res. 2014;20(5):209-17. doi: 10.1159/000357865.

PMID:
24557083
18.

Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.

O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ.

Psychopharmacology (Berl). 2002 Feb;160(1):19-29.

PMID:
11862370
19.

A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.

Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB.

Arch Gen Psychiatry. 1999 Aug;56(8):719-24.

PMID:
10435606
20.

The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients.

François C, Rahhali N, Chalem Y, Sørensen P, Luquiens A, Aubin HJ.

PLoS One. 2015 Jun 8;10(6):e0129289. doi: 10.1371/journal.pone.0129289.

Items per page

Supplemental Content

Support Center